Loading...
Market
What will be the impact of Oxbryta withdrawal on Pfizer's Q4 2024 revenue?
2
Resolution / Starting Odds
Decrease by more than 5% • 25%
Decrease by 1-5% • 25%
No significant change • 25%
Increase • 25%
Pfizer's official financial statements
Story
Pfizer Withdraws Sickle Cell Treatment Oxbryta from Global Markets Due to Safety Concerns, $5.4 Billion Acquisition Impacted
Sep 25, 2024, 09:30 PM
Pfizer Inc. announced it is voluntarily withdrawing all lots of its sickle cell disease treatment, Oxbryta (voxelotor), from worldwide markets due to safety concerns. The decision follows data indicating an imbalance in vaso-occlusive crises and fatal events associated with the drug. Oxbryta was acquired by Pfizer in a $5.4 billion deal with Global Blood Therapeutics in 2022.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
No action taken • 25%
Warning issued • 25%
Fine imposed • 25%
Other sanctions • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $8 billion • 25%
$8 billion to $10 billion • 25%
$10 billion to $12 billion • 25%
More than $12 billion • 25%
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
Paxlovid • 25%
Comirnaty • 25%
Prevnar • 25%
Other • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than $85 billion • 25%
$85 billion to $90 billion • 25%
$90 billion to $95 billion • 25%
More than $95 billion • 25%
Less than $60 billion • 25%
$60 billion to $65 billion • 25%
$65 billion to $70 billion • 25%
More than $70 billion • 25%